Program
formoterol
Also written as “Formoterol Fumarate”, “budesonide/formoterol” and “Formoterol”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Bronchitis, Chronic · Asthma, Exercise-Induced, led by 18 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 632 open or running | phase 4since Jan 4, 2006 | Sep 13, 2005 | May 31, 2027phase 4 · NCT07073950 |
| Chiesi Farmaceutici | 200 open or running | phase 4since Nov 29, 2010 | Oct 30, 2006 | none ahead |
| Viatris | 160 open or running | phase 4since Nov 29, 2011 | Sep 13, 2005 | none ahead |
| Novartis | 60 open or running | phase 4since Jul 26, 2005 | Jul 26, 2005 | none ahead |
| Sumitomo Pharma | 60 open or running | phase 4since Jan 17, 2007 | Jul 8, 2003 | none ahead |
| SkyePharma | 50 open or running | phase 3since Oct 27, 2006 | Oct 27, 2006 | none ahead |
| Eurofarma Laboratorios | 30 open or running | phase 3since Oct 23, 2009 | Oct 23, 2009 | none ahead |
| Mundipharma | 30 open or running | phase 4since Jun 15, 2015 | Oct 14, 2009 | none ahead |
| Ache Laboratorios Farmaceuticos | 20 open or running | phase 3since Mar 9, 2011 | Mar 9, 2011 | none ahead |
| Boehringer Ingelheim | 20 open or running | phase 2since Sep 11, 2014 | Sep 11, 2014 | none ahead |
| intech-biopharm-ltd | 20 open or running | phase 1since Jul 25, 2016 | Jul 25, 2016 | none ahead |
| Orion Corporation, Orion Pharma | 20 open or running | phase 2since Aug 24, 2009 | Aug 24, 2009 | none ahead |
| Zambon SpA | 20 open or running | phase 1since Sep 2, 2014 | Sep 2, 2014 | none ahead |
| Chenpon Pharmaceutical | 10 open or running | phase 3since Aug 24, 2026 | Aug 24, 2026 | none ahead |
| kindeva-drug-delivery | 10 open or running | phase 3since Jan 6, 2017 | Jan 6, 2017 | none ahead |
| Merck | 10 open or running | phase 4since Aug 30, 2005 | Aug 30, 2005 | none ahead |
| neutec-ar-ge-san-ve-tic-a-s | 10 open or running | phase 4since Oct 6, 2016 | Oct 6, 2016 | none ahead |
| Teva Pharmaceutical Industries | 10 open or running | phase 3since Jul 1, 2015 | Jul 1, 2015 | none ahead |
Also a collaborator on its studies: parexel, ciscrp, eresearchtechnology, Menarini Group, integrated-therapeutics-group and Pacira BioSciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Mar 9, 2011.
- Aug 23, 2017Phase 3 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT03268226 · 20 enrolled · Belgium, Hungary
- Nov 10, 2017Phase 3 study in AsthmaMundipharma · NCT03387241 · 330 enrolled · China
- Sep 24, 2018Phase 3 study in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT03836677 · 23 enrolled · Belgium, Netherlands
- Jul 28, 2020Phase 1 study in Asthmaintech-biopharm-ltd · NCT04494321 · 99 enrolled · Taiwan
- Oct 26, 20202 phase 3 studies in AsthmaAstraZeneca · NCT04609904, NCT04609878
- May 3, 2021Phase 3 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT04876677 · 25 enrolled · Belgium, Hungary
- Jan 10, 2022Phase 3 study in AsthmaAstraZeneca · NCT05202262 · 645 enrolled · United States, Canada, Germany and more
- Mar 4, 2022Phase 3 study in AsthmaChiesi Farmaceutici · NCT05292586 · 1,377 enrolled · United States
- Feb 23, 2023Phase 3 study in AsthmaAstraZeneca · NCT05755906 · 374 enrolled · United States, Canada, Czechia and more
- Sep 28, 2023Phase 3 study in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT06067828 · 171 enrolled · United States, Canada, China and more
- Feb 21, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT06283966 · 5,250 planned · United States, Argentina, Australia and more
- Jul 17, 2025Phase 4 study in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT07073950 · 56 planned · Germany, United Kingdom
- Feb 20, 2026Phase 1 study in AsthmaAstraZeneca · NCT07433569 · 16 enrolled · United States
- Aug 24, 2026Chenpon Pharmaceutical's first study: phase 3 study in AsthmaNew to Chenpon PharmaceuticalChenpon Pharmaceutical · NCT07790159 · 338 enrolled · China
Ahead
- May 31, 2027Primary completion: phase 4 study in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT07073950
- Dec 3, 2027Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT06283966
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The newest 60 of 137 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07790159Asthma · China | 3 | Completed | Chenpon Pharmaceutical | Sep 27, 2024 | 338 |
| NCT07433569Asthma · United States | 1 | Completed | AstraZeneca | Jun 26, 2026 | 16 |
| NCT07073950Pulmonary Disease, Chronic Obstructive · Germany, United Kingdom | 4 | Recruiting | AstraZeneca | May 31, 2027 | 56 |
| NCT06283966Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Dec 3, 2027 | 5,250 |
| NCT06067828Pulmonary Disease, Chronic Obstructive · United States, Canada, China and more | 3 | Completed | AstraZeneca | Jan 22, 2026 | 171 |
| NCT05755906Asthma · United States, Canada, Czechia and more | 3 | Completed | AstraZeneca | Nov 19, 2024 | 374 |
| NCT05292586Asthma · United States | 3 | Completed | Chiesi Farmaceutici | Jun 24, 2024 | 1,377 |
| NCT05202262Asthma · United States, Canada, Germany and more | 3 | Completed | AstraZeneca | Feb 26, 2025 | 645 |
| NCT04876677Pulmonary Disease, Chronic Obstructive · Belgium, Hungary | 3 | Completed | Chiesi Farmaceutici | Jan 3, 2022 | 25 |
| NCT04609904Asthma · United States, Brazil, China and more | 3 | Completed | AstraZeneca | Mar 20, 2025 | 2,187 |
| NCT04609878Asthma · United States, Argentina, Belgium and more | 3 | Completed | AstraZeneca | Mar 21, 2025 | 2,274 |
| NCT04494321Asthma · Taiwan | 1 | Completed | intech-biopharm-ltd | Nov 17, 2017 | 99 |
| NCT03836677Pulmonary Disease, Chronic Obstructive · Belgium, Netherlands | 3 | Completed | AstraZeneca | Nov 11, 2019 | 23 |
| NCT03387241Asthma · China | 3 | UNKNOWN | Mundipharma | Dec 30, 2019 | 330 |
| NCT03268226Pulmonary Disease, Chronic Obstructive · Belgium, Hungary | 3 | Completed | Chiesi Farmaceutici | Jan 30, 2019 | 20 |
| NCT03162055Pulmonary Disease, Chronic Obstructive · United States, Bulgaria, Canada and more | 3 | Completed | AstraZeneca | May 4, 2018 | 1,119 |
| NCT03181880Pulmonary Disease, Chronic Obstructive | 4 | Withdrawn | AstraZeneca | Dec 3, 2018 | 0 |
| NCT03022097Pulmonary Disease, Chronic Obstructive · China, India, Philippines and more | 3 | Completed | AstraZeneca | Apr 14, 2022 | 1,625 |
| NCT03015259Asthma · United States | 3 | Completed | kindeva-drug-delivery | Feb 8, 2018 | 1,762 |
| NCT02975843Pulmonary Disease, Chronic Obstructive | 1 | Completed | Chiesi Farmaceutici | Mar 21, 2017 | 28 |
| NCT02988869Pulmonary Disease, Chronic Obstructive · Turkey | 4 | Completed | neutec-ar-ge-san-ve-tic-a-s | Aug 2017 | 84 |
| NCT02850484Asthma | 1 | Completed | intech-biopharm-ltd | May 2016 | 99 |
| NCT02796651Pulmonary Disease, Chronic Obstructive · United States | 2 | Completed | AstraZeneca | Dec 7, 2016 | 132 |
| NCT02796677Pulmonary Disease, Chronic Obstructive · United States, Bulgaria, Czechia and more | 3 | Completed | AstraZeneca | Jun 8, 2017 | 1,595 |
| NCT02766608Pulmonary Disease, Chronic Obstructive · United States, Canada, Czechia and more | 3 | Completed | AstraZeneca | Dec 1, 2017 | 2,389 |
| NCT03262012Pulmonary Disease, Chronic Obstructive · Japan | 3 | Completed | AstraZeneca | Jun 15, 2018 | 416 |
| NCT03073057Asthma · Finland | 1 | Completed | Orion Corporation, Orion Pharma | Mar 2016 | 20 |
| NCT02685293Pulmonary Disease, Chronic Obstructive · United States | 3 | Terminated | AstraZeneca | Jun 6, 2018 | 4 |
| NCT02631941Asthma · United Kingdom | 1 | Completed | Zambon SpA | Jul 2016 | 91 |
| NCT02536508Pulmonary Disease, Chronic Obstructive · United States | 3 | Completed | AstraZeneca | Sep 12, 2017 | 627 |
| NCT02497001Pulmonary Disease, Chronic Obstructive · United States, Canada, China and more | 3 | Completed | AstraZeneca | Jan 5, 2018 | 1,902 |
| NCT02495168Asthma · United States | 3 | Completed | Teva Pharmaceutical Industries | May 31, 2018 | 1,714 |
| NCT02491970Asthma | 4 | Terminated | Mundipharma | Apr 6, 2017 | 15 |
| NCT02465567Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Jul 26, 2019 | 8,588 |
| NCT02424344Pulmonary Disease, Chronic Obstructive · Canada, Germany, Hungary and more | 4 | Completed | AstraZeneca | Jul 25, 2016 | 267 |
| NCT02347085Pulmonary Disease, Chronic Obstructive | 3 | Completed | AstraZeneca | Jun 1, 2015 | 43 |
| NCT02347072Pulmonary Disease, Chronic Obstructive | 3 | Completed | AstraZeneca | Aug 1, 2015 | 80 |
| NCT02343458Pulmonary Disease, Chronic Obstructive · United States, China, Czechia and more | 3 | Completed | AstraZeneca | Aug 31, 2017 | 1,756 |
| NCT02242240Pulmonary Disease, Chronic Obstructive | 2 | Completed | Boehringer Ingelheim | Dec 2001 | 95 |
| NCT02238119Pulmonary Disease, Chronic Obstructive | 2 | Completed | Boehringer Ingelheim | Aug 2002 | 74 |
| NCT02237508Asthma · United Kingdom | 1 | Completed | Zambon SpA | Feb 2015 | 90 |
| NCT02196714Pulmonary Disease, Chronic Obstructive · United States | 1 | Completed | AstraZeneca | Sep 2014 | 24 |
| NCT02196077Pulmonary Disease, Chronic Obstructive · United States | 2 | Completed | AstraZeneca | Mar 1, 2015 | 180 |
| NCT02189304Pulmonary Disease, Chronic Obstructive · United States | 1 | Completed | AstraZeneca | Sep 1, 2014 | 59 |
| NCT02119234Pulmonary Disease, Chronic Obstructive · Poland | 1 | Completed | Chiesi Farmaceutici | Feb 2015 | 36 |
| NCT02040597Pulmonary Disease, Chronic Obstructive · Poland | 1 | Completed | Chiesi Farmaceutici | Apr 2015 | 42 |
| NCT01917331Pulmonary Disease, Chronic Obstructive · Hungary | 3 | Completed | Chiesi Farmaceutici | Jan 14, 2016 | 1,368 |
| NCT01908140Pulmonary Disease, Chronic Obstructive · Austria, Bulgaria, Canada and more | 3 | Completed | AstraZeneca | Aug 2014 | 933 |
| NCT01854658Pulmonary Disease, Chronic Obstructive · United States | 3 | Completed | AstraZeneca | Mar 2015 | 1,615 |
| NCT01845025Asthma · United States | 4 | Terminated | Novartis | May 2016 | 827 |
| NCT01794780Pulmonary Disease, Chronic Obstructive · China | 4 | Completed | Novartis | May 25, 2015 | 2,229 |
| NCT01676987Asthma | 3 | Completed | Ache Laboratorios Farmaceuticos | Sep 2010 | 181 |
| NCT01658891Asthma in Children · Denmark | 3 | Withdrawn | Chiesi Farmaceutici | Nov 2015 | 0 |
| NCT01641081Asthma · United States | 2 | Completed | AstraZeneca | Feb 2013 | 174 |
| NCT01584492Asthma · Poland, Ukraine | 2 | Completed | Chiesi Farmaceutici | Feb 2013 | 59 |
| NCT01551888Pulmonary Disease, Chronic Obstructive · United States | 2 | Completed | AstraZeneca | Mar 2012 | 24 |
| NCT01488019Pulmonary Disease, Chronic Obstructive · United States | 4 | Completed | Viatris | Jan 2016 | 1,071 |
| NCT01475032Asthma · Bulgaria, France, Germany and more | 3 | Completed | Chiesi Farmaceutici | Sep 2012 | 638 |
| NCT01398111Pulmonary Disease, Chronic Obstructive · Belgium | 1 | Completed | Chiesi Farmaceutici | Aug 2011 | 44 |
| NCT01393145Pulmonary Disease, Chronic Obstructive | 3 | Withdrawn | Ache Laboratorios Farmaceuticos | Aug 2012 | 0 |
How it is read
Names in the registry
- “Formoterol Fumarate”, 14 entries
- “budesonide/formoterol”, 10 entries
- “Formoterol”, 9 entries
- “Fluticasone Propionate/Formoterol Fumarate”, 9 entries
- “BGF MDI 320/14.4/9.6 μg”, 6 entries
Conditions, from the studies’ own filings
- Asthma, 75 studies
- Pulmonary Disease, Chronic Obstructive, 71 studies
- Bronchitis, Chronic, 2 studies
- Asthma, Exercise-Induced, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.